The global urology surgical instruments market is expected to experience a CAGR of 8% during the forecast period of 2025 to 2033. Urology surgical instruments play a critical role in diagnosing and treating various urological conditions, such as kidney stones, urinary incontinence, and prostate disorders. These instruments are utilized in both traditional open surgeries and minimally invasive procedures, offering greater precision and efficiency to urologists and surgeons. One of the primary drivers of market growth is the rising prevalence of urological disorders worldwide.
The veterinary biomarkers market is expected to grow at a CAGR of 12.5% during the forecast period of 2025 to 2033, driven by the increasing prevalence of animal diseases and the growing focus on animal healthcare. Biomarkers play a crucial role in veterinary medicine as they help in the early detection, diagnosis, and monitoring of diseases in animals. These biomarkers can be measured in various biological samples, such as blood, urine, and tissues, providing valuable insights into the health status of animals.
The drug-device combination products market is a rapidly growing sector within the healthcare industry that combines the benefits of pharmaceuticals and medical devices. These products consist of a combination of drugs and medical devices, which are designed to work together to deliver therapeutic treatments and enhance patient outcomes. The market revenue for drug-device combination products has been steadily increasing in recent years, driven by factors such as the rising prevalence of chronic diseases, technological advancements, and the growing demand for personalized medicine.
The photoacoustic imaging market is a rapidly growing segment in the field of medical imaging. The market is expected to register a CAGR of 16% during the forecast period of 2025 to 2033. Photoacoustic imaging combines the principles of laser-induced photoacoustic effect and ultrasound imaging to provide high-resolution and functional imaging capabilities. This technology has gained significant attention due to its non-invasive nature, real-time imaging capabilities, and ability to visualize deep tissue structures with excellent contrast.
The veterinary MRI market is expected to grow at a CAGR of 6.5% during the forecast period of 2025 to 2033. Animal products such as meat, milk, and eggs were unable to reach markets as a result of the disruption in the supply chain. In response to the disruption in the demand-supply chain, the Food and Agriculture Organization published in April 2020 a new policy regarding the production of livestock and the supply chain of livestock products during the pandemic to ensure adequate livestock production.
The global market for point-of-care molecular diagnostics is anticipated to expand at a CAGR of 8.5% during the forecast period of 2025 and 2033. The rise of the point-of-care molecular diagnostics market is primarily driven by the increasing prevalence of infectious diseases and cancer, as well as the growing desire of end users for point-of-care molecular testing due to its attractive features. Medical personnel has long utilized molecular diagnostics in laboratories and other healthcare settings.
The global market for aneurysm clips is anticipated to expand at a CAGR of over 7% during the forecast period of 2025 to 2033. Rapid development in information dissemination via the Internet has significantly contributed to the adoption of aneurysm clips and disease treatments. Clinical management information, availability of aneurysm clips, pricing, defects in aneurysm clips material biocompatibility, physician feedback, R&D, etc., are all available to the general public via open-source websites.
The global wearable injector market is expected to grow at a CAGR of 12% CAGR during the forecast period of 2025 to 2033. These devices permit the injection of large volume of dosage via subcutaneous route for long duration, which offers benefits to drug developers, clinicians and patients. Most of the instances biologic therapeutics are parenteral delivery wherein high volume injection doses are often needed. Biologic therapeutics development is growing at a faster pace compared to other medication forms, this growth in the biologic market is said to in parallel drive the emergence of wearable injectors.
The Chimeric antigen receptor- T Cell Therapy Market is anticipated to grow at a significantly healthy CAGR of 35% during the forecast period of 2025 to 2033. The increase is primarily due to an increase in cancer patients’ rate combined with increased awareness of the therapy. This report covers all the qualitative and quantitative aspects of the Car-T Cell Therapy Market and also covers key drivers, restraints, challenges, and opportunities that are impacting the growth opportunities of the market, and its future market trends.
The global enteral syringe market is increasing proficiently, expected to grow at a CAGR of 5.3%. Globally, the rising commonness of chronic illness and numerous lifestyle disorders will drive the overall growth of the market. Enteral syringes deliver nutritional therapy or medications to different age groups including pediatrics, and adult patients. Enteral syringes are available in different sizes ranging from 1ml to 60 ml and are generally used for patients in hospitals/clinics, and home care. Globally increasing neonatal admissions, gastrointestinal diseases, cancer, malnutrition and overall management of treatment for various diseases are major factors driving the overall growth of the enteral syringes market.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.